Breakthroughs

Decoding the Immune Response in Early-Stage Bladder Cancer with Joshua Meeks, MD, PhD

October 26, 2026·23 min
Episode Description from the Publisher

Why does a standard immunotherapy work remarkably well for some bladder cancer patients, but fail for others? In this episode, Northwestern Medicine physician-scientist Joshua Meeks, MD, PhD, breaks down his recent research published in the Journal of Clinical Investigation and European Urology uncovering how the tumor microenvironment and immune cellular communication influence response to Bacillus Calmette-Guérin (BCG) immunotherapy. Find out how single-cell RNA sequencing, macrophage–T-cell interactions, and urinary tumor DNA biomarkers are paving the way for targeted, personalized bladder cancer care.

Podzilla Summary coming soon

Sign up to get notified when the full AI-powered summary is ready.

Get Free Summaries →

Free forever for up to 3 podcasts. No credit card required.

Listen to This Episode

Get summaries like this every morning.

Free AI-powered recaps of Breakthroughs and your other favorite podcasts, delivered to your inbox.

Get Free Summaries →

Free forever for up to 3 podcasts. No credit card required.